gineco
ro
infertilitate
paracrin şi autocrin în sens favorabil Corticosteroizii cu putere mare de schemele de administrare.
producerii ovulaţiei. inhibiţie a secreţiei de ACTH (de tipul 8 Se fac eforturi pentru
Agoniştii dopaminergici (bromo- dexametazonei) sunt preferaţi pentru identificarea schemelor optime
criptina şi cabergolina) sunt utilizaţi reglarea menstruaţiei şi reinstalarea pentru obţinerea unui procent crescut
nu doar în tratamentul infertilităţii fertilităţii la pacientele cu sindrom de sarcini per ciclu de stimulare fără
din hiperprolactinemia tumorală adrenogenital congenital. creşterea concomitentă a riscului
sau netumorală, dar se vehiculează de malformaţii fetale sau de
ideea că în unele cazuri de infertilitate Concluzii hiperstimulare ovariană.
idiopatică se produce o creştere 8 Paleta medicaţiei utilizate 8 Acestea vor fi reluate pe larg
temporară a valorilor prolactinei la pentru inducerea ovulaţiei în vederea - alături de rezultatele personale
momentul ovulaţiei, care ar compromite procedeelor de reproducere umană obţinute prin utilizarea celor mai
fertilitatea; acest vârf secretor poate asistată este în consecinţă deosebit cunoscute clase de inductori de
fi contrabalansat de administrarea de de largă, atât în ceea ce priveşte ovulaţie - în numerele următoare ale
agonişti dopaminergici. preparatele utilizate, cât şi dozele şi revistei.
Bibliografie
1. Agarwal SK, Buyalos RP (1995) – Corpus luteum function 11. Coppola F, Poti ER, Barusi L, Ferrari B, Salvarani MC and
and pregnancy rates with clomiphene citrate therapy: com- Vadora E (2003) Profound luteinizing hormone suppres-
parison of human chorionic gonadotrophin-induced versus sion induces a deleterious follicular environment during
spontaneous ovulation. – Hum Reprod, 10:328; assisted reproduction technology. Fertil Steril 79, 459–460
2. Al-Fadhli R, Sylvestre C, Buckett W, Tan SL, Tulandi T. A 12. Cowan DB, Seifer DB (1997) – Clinical reproductive medi-
randomized trial of superovulation with two different doses cine. - 61-68, 231-238;
of letrozole. Fertil Steril. 2006 Jan;85(1):161-4. 13. Demirel LC, Weiss JM, Polack S et al (2000) – Effect of go-
3. Balasch J, Penarrubia J, Fabregues F, Vidal E, Casamitjana R, nadotropin- releasing hormone antagonist ganirelix on
Manau D, Carmona F, Creus M and Vanrell JA (2003) Ovar- cyclic adenosine monophosphate accumulation of human
ian responses to recombinant FSH or HMG in normogo- granulosa—lutein cells. – Fertil Steril, 74:1001-1007;
nadotrophic women following pituitary desensitization by 14. Dickey RP, Taylor SN, Curole DAN, Rye PH, Pyrzak R (1996)
a depot GnRH agonist for assisted reproduction. Reprod – Incidence of spontaneous abortion in clomiphene preg-
Biomed Online 7, 35–42. nancies. – Hum Reprod, 11:2623;
4. Balasch J, Vidal E, Penarrubia J, Casamitjana R, Carmona F, 15. Dor J, Bider D, Shulman A, et al (2000) – Effects of gonado-
Creus M, Fabregues F and Vanrell JA (2001) Suppression of tropin-releasing hormone agonists on human ovarian ste-
LH during ovarian stimulation: analysing threshold values roid secretion in vivo and in vitro - results of a prospective,
and effects on ovarian response and the outcome of assisted randomized in vitro fertilization study. – Hum Reprod,
reproduction in down-regulated women stimulated with re- 15:125-1230;
combinant FSH. Hum Reprod 16, 1636–1643 16. Esposito MA, Barnhart KT, Coutifaris C and Patrizio P
5. Bedaiwy MA, Forman R, Mousa NA, Al Inany HG, Casper RF (2001) Role of periovulatory luteinizing hormone concen-
2006 Cost effectiveness of aromatase inhibitor co-treatment trations during assisted reproductive technology cycles
for controlled ovarian stimulation. Hum Reprod 21:2838– stimulated exclusively with recombinant follicle-stimulat-
2844 ing hormone. Fertil Steril 75, 519–524
6. Bedaiwy MA, Mousa NA, Esfandiari N, Forman R, Casper 17. Filicori M, Cognigni GE, Pocognoli P, Tabarelli C, Ferlini F,
RF. Follicular phase dynamics with combined aromatase in- Perri T and Parmegiani L (2003) Comparison of controlled
hibitor and follicle stimulating hormone treatment. J Clin ovarian stimulation with human menopausal gonadotro-
Endocrinol Metab. 2007 Mar;92(3):825-33. pin or recombinant follicle-stimulating hormone. Fertil
7. Bergh C, Howles CM, Borg K, et al (1997) – Recombinant hu- Steril 80, 390–397.
man follicle stimulating hormone (r-hFSH; Gonal-F) versus 18. Filicori M, Flamigni C, Dellai P, Cognigni G, Michelacci L,
higly purified urinary FSH (Metrodin HP): results of a ran- Arnone R, Sambataro M, Falbo A (1994) – Treatment of an-
domized comparative study in women undergoing assisted ovulation with pulsatile gonadotropin-releasing hormone;
reproductive techniques. – Hum Reprod, 12:2133-2139 prognostic factors and clinical results in 600 cycles. – J
8. Carr JS, Reid RL (1990) – Ovulation induction with gonado- Clin Endocrinol Metab, 79:1215
tropin-releasing hormone (GnRH). – Seminars Reprod En- 19. Filicori M, Flamingi C (1995) – Treatment with GnRH ana-
docrinol, 8:174; logs. Controversis and perspectives - pag. 3 – 30
9. Cédrin-Durnerin I., Grange-Dujardin D., Laffy A., Parneix I., 20. Filicori M, Flamingni C, Campaniello E, Meriggiola MC,
Massin N., Galey J., Théron L, Wolf J.P., Conord C., Clément Michelacci L, Valdiserri A, Ferrari P (1990) – Polycystic
P., Jayot S., Hugues J.N. Recombinant human LH supplemen- ovary syndrome: abnormalities and management with
tation during GnRH antagonist administration in IVF/ICSI pulsatile gonadotropin-releasing hormone and gonado-
cycles: a prospective randomized study. Human Reproduc- tropin-releasing hormone analogs. – Am J Obstet Gynecol,
tion 2004 19(9):1979-1984; 163:17737;
10. Cela V, Artini PG, Cattani R, Matteuci C, Vite A, Valentino 21. Garcia-Velasco JA, Moreno L, Pacheco A, Guillen A, Duque
V, Taponeco F, Genazzani AR (2000) - GnRH analogs and L, Requena A, Pellicer A 2005 The aromatase inhibitor
granulosa cells function. In Gynecol. Endocr., vol.15, sup- letrozole increases the concentration of intraovarian an-
pl.5, pag. 50; drogens and improves in vitro fertilization outcome in low
pag. 38 Vol. 4, Nr. 1 /februarie 2008
Page 1  |  Page 2  |  Page 3  |  Page 4  |  Page 5  |  Page 6  |  Page 7  |  Page 8  |  Page 9  |  Page 10  |  Page 11  |  Page 12  |  Page 13  |  Page 14  |  Page 15  |  Page 16  |  Page 17  |  Page 18  |  Page 19  |  Page 20  |  Page 21  |  Page 22  |  Page 23  |  Page 24  |  Page 25  |  Page 26  |  Page 27  |  Page 28  |  Page 29  |  Page 30  |  Page 31  |  Page 32  |  Page 33  |  Page 34  |  Page 35  |  Page 36  |  Page 37  |  Page 38  |  Page 39  |  Page 40  |  Page 41  |  Page 42  |  Page 43  |  Page 44  |  Page 45  |  Page 46  |  Page 47  |  Page 48  |  Page 49  |  Page 50  |  Page 51  |  Page 52  |  Page 53  |  Page 54  |  Page 55  |  Page 56  |  Page 57  |  Page 58  |  Page 59  |  Page 60  |  Page 61  |  Page 62  |  Page 63  |  Page 64  |  Page 65  |  Page 66  |  Page 67  |  Page 68